IN THE CLAIMS:

The following listing of claims replaces all prior versions and listings of claims in the application.

1.-12. (Canceled)

13. (Previously allowed) A pharmaceutical composition comprising isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid or a pharmaceutically acceptable salt or hydrate thereof together with a pharmaceutically acceptable carrier or excipient, which orthorhombic crystalline form (i) is substantially free of monoclinic crystalline forms as evidenced by powder x-ray diffraction (PXRD) analysis showing the absence of doublet peaks between about 11.5 and 16 (2-Theta scale), and (ii) exhibits at least twice the solubility of a monoclinic crystalline form at 30 °C in aqueous ethanol.

14. (Previously allowed) The pharmaceutical composition of claim 13, which is formulated as a tablet.

15. (Previously allowed) The pharmaceutical composition of claim 13, which is formulated as a capsule.

16. (Previously allowed) The pharmaceutical composition of claim 13, which further comprises lactose and microcrystalline cellulose.

17. (Previously allowed) The pharmaceutical composition of claim 14, which is the tablet weighing between 250 and 500 mg.

18. (Previously allowed) Isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid, which

orthorhombic crystalline form (i) is substantially free of monoclinic crystalline forms as evidenced by powder x-ray diffraction (PXRD) analysis showing the absence of doublet peaks between about 11.5 and 16 (2-Theta scale), and (ii) exhibits at least twice the solubility of a monoclinic crystalline form at 30 °C in aqueous ethanol.

19. (Previously allowed) A method of treating an allergic disease comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid or a pharmaceutically acceptable salt or hydrate thereof, which orthorhombic crystalline form (i) is substantially free of monoclinic crystalline forms as evidenced by powder x-ray diffraction (PXRD) analysis showing the absence of doublet peaks between about 11.5 and 16 (2-Theta scale), and (ii) exhibits at least twice the solubility of a monoclinic crystalline form at 30 °C in aqueous ethanol.

20. (Previously allowed) A method of claim 19 in which the allergic disease includes asthma.

21. (New) The method of claim 20 in which the asthma is bronchial asthma.

22. (New) The pharmaceutical composition of claim 13, which comprises the acid.

23. (New) The pharmaceutical composition of claim 14, which is the tablet weighing between 100 mg and 1000 mg.

24. (New) The pharmaceutical composition of claim 13 in which the aqueous ethanol is a mixture of ethanol and water in a ratio of 2:1.